Abstract
Dysregulated miRNAs have been demonstrated to be associated with the progression of colon cancer. The dysregulation of miR-3133 was observed in colon cancer, but its specific function was unclear. The functional role of miR-3133 in colon cancer was investigated in this study. A total of 113 colon cancer patients were included. miR-3133 expression was evaluated by PCR. The biological effects of miR-3133 in colon cancer cells were assessed with the help of the transwell and CCK8 assay. The prognostic value of miR-3133 was estimated by a series of statistical analyses. In mechanism, the interaction between miR-3133 and RUFY3 was evaluated by luciferase reporter. The significant downregulation of miR-3133 was observed in colon cancer, which showed a significant association with the advanced TNM stage and bad survival of patients. miR-3133 and TNM stage were identified as independent prognostic indicators of colon cancer. In vitro, the overexpression of miR-3133 exerted a dramatically inhibitory effect on cellular processes of colon cancer, which were enhanced by miR-3133 knockdown. Additionally, miR-3133 could negatively regulate the luciferase activity and expression of RUFY3, which was speculated as the underlying mechanism mediating the regulatory effect of miR-3133. miR-3133 functioned as a prognostic biomarker indicating the progression and prognosis of colon cancer, and it also served as a tumor suppressor via negatively regulating RUFY3, which provides a potential therapeutic target for colon cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Ahmed FE (2014) miRNA as markers for the diagnostic screening of colon cancer. Expert Rev Anticancer Ther 14:463–485. https://doi.org/10.1586/14737140.2014.869479
Angarita FA, Oshi M, Yamada A, Yan L, Matsuyama R, Edge SB et al (2022) Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer. Breast Cancer Res Treat 192:19–32. https://doi.org/10.1007/s10549-021-06482-3
Beni FA, Kazemi M, Dianat-Moghadam H, Behjati M (2022) MicroRNAs regulating Wnt signaling pathway in colorectal cancer: biological implications and clinical potentials. Funct Integr Genomics 22:1073–1088. https://doi.org/10.1007/s10142-022-00908-x
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK et al (2018) NCCN guidelines insights: colon cancer, Version 2.2018. J Natl Compr Canc Netw 16:359–369. https://doi.org/10.6004/jnccn.2018.0021
Boeker M, Fran A, F, Bronsert, P, Schulz, S, (2016) TNM-O: ontology support for staging of malignant tumours. J Biomed Semantics 7:64. https://doi.org/10.1186/s13326-016-0106-9
Cappell MS (2008) Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am 37(1–24):v. https://doi.org/10.1016/j.gtc.2007.12.00
Chen X (2019) Expression of microRNA-3133 correlates with the prognosis in patients with clear cell renal cell carcinoma. Medicine (Baltimore) 98:e16008. https://doi.org/10.1097/md.0000000000016008
Chowdhury SG, Ray R, Karmakar P (2022) Exosomal miRNAs-a diagnostic biomarker acting as a guiding light in the diagnosis of prostate cancer. Funct Integr Genomics 23:23. https://doi.org/10.1007/s10142-022-00951-8
Dienstmann R, Salazar R, Tabernero J (2015) Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 33:1787–1796. https://doi.org/10.1200/JCO.2014.60.0213
Ganepola GA, Nizin J, Rutledge JR, Chang DH (2014) Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World J Gastrointest Oncol 6:83–97. https://doi.org/10.4251/wjgo.v6.i4.83
Jin W, Shi J, Liu M (2019) Overexpression of miR-671-5p indicates a poor prognosis in colon cancer and accelerates proliferation, migration, and invasion of colon cancer cells. Onco Targets Ther 12:6865–6873. https://doi.org/10.2147/OTT.S219421
Kahi CJ, Anderson JC, Rex DK (2013) Screening and surveillance for colorectal cancer: state of the art. Gastrointest Endosc 77:335–350. https://doi.org/10.1016/j.gie.2013.01.002
Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S et al (2010) Colon cancer. Crit Rev Oncol Hematol 74:106–133. https://doi.org/10.1016/j.critrevonc.2010.01.010
Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4:199–227. https://doi.org/10.1146/annurev.pathol.4.110807.092222
Li ZN, Ge MX, Cao LJ, Yuan ZF (2020) lncRNA RHPN1-AS1 serves as a sponge for miR-3133 modulating the cell proliferation of retinoblastoma through JAK2. Biomed Res Int 2020:3502981. https://doi.org/10.1155/2020/3502981
Li R, Zhang S, Liu G (2022) Identification and validation of a pyroptosis-related prognostic model for colorectal cancer. Funct Integr Genomics 23:21. https://doi.org/10.1007/s10142-022-00935-8
Men W, Li W, Li Y, Zhao J, Qu X, Li P et al (2019) RUFY3 predicts poor prognosis and promotes metastasis through epithelial-mesenchymal transition in lung adenocarcinoma. J Cancer 10:6278–6285. https://doi.org/10.7150/jca.35072
O'NEILL C P & DWYER, R M (2020) Nanoparticle-based delivery of tumor suppressor microRNA for cancer therapy. Cells 9. https://doi.org/10.3390/cells9020521
Pi Eros M, Parkin DM, Ward K, Chokunonga E, Ervik M, Farrugia H et al (2019) Essential TNM: a registry tool to reduce gaps in cancer staging information. Lancet Oncol 20:e103–e111. https://doi.org/10.1016/s1470-2045(18)30897-0
Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L et al (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68:6416–6424. https://doi.org/10.1158/0008-5472.CAN-07-6110
Sonnenberg WR (2017) Gastrointestinal malignancies. Prim Care 44:721–732. https://doi.org/10.1016/j.pop.2017.07.013
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G et al (2018) Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer 17:147. https://doi.org/10.1186/s12943-018-0897-7
Wang YN, Chen ZH, Chen WC (2017) Novel circulating microRNAs expression profile in colon cancer: a pilot study. Eur J Med Res 22:51. https://doi.org/10.1186/s40001-017-0294-5
Wang J, Wang L, Zhang C (2021) miR-765 acts as a tumor promoter and indicates poor prognosis in non-small cell lung cancer. Onco Targets Ther 14:4335–4343. https://doi.org/10.2147/OTT.S284212
Xie R, Wang J, Liu X, Wu L, Zhang H, Tang W et al (2017) RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer. Sci Rep 7:3709. https://doi.org/10.1038/s41598-017-04011-1
Xie R, Wang J, Tang W, Li Y, Peng Y, Zhang H et al (2017) Rufy3 promotes metastasis through epithelial-mesenchymal transition in colorectal cancer. Cancer Lett 390:30–38. https://doi.org/10.1016/j.canlet.2017.01.001
Xu M, Cao L, Zhang X, Zhuang Y, Zhang Y, Wang Q et al (2020) miR3133 inhibits proliferation and angiogenesis by targeting the JUNB/VEGF pathway in human umbilical vein endothelial cells. Oncol Rep 44:1699–1708. https://doi.org/10.3892/or.2020.7715
Yang C, Zhang G, Zhang Y, Zhang S, Li J, Liu Y (2021) Exosome miR-134-5p restrains breast cancer progression via regulating PI3K/AKT pathway by targeting ARHGAP1. J Obstet Gynaecol Res. https://doi.org/10.1111/jog.14983
Yu M, Yu HL, Li QH, Zhang L, Chen YX (2019) miR-4709 overexpression facilitates cancer proliferation and invasion via downregulating NR3C2 and is an unfavorable prognosis factor in colon adenocarcinoma. J Biochem Mol Toxicol 33:e22411. https://doi.org/10.1002/jbt.22411
Zeng M, Zhu L, Li L, Kang C (2017) miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett 22:12. https://doi.org/10.1186/s11658-017-0041-5
Zhang Y, Sheng, S, Liang, Q, Zhang, L (2020) Olmesartan inhibits age-associated migration and invasion of human aortic vascular smooth muscle cells by upregulating miR-3133 axis. Nan Fang Yi Ke Da Xue Xue Bao 40: 499-505. https://doi.org/10.12122/j.issn.1673-4254.2020.04.08
Zhang Y, Ni, W Qin, L (2021) RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition. Aging (Albany NY) 13: 21283–21293. https://doi.org/10.18632/aging.203444
Author information
Authors and Affiliations
Contributions
All authors designed this study. H. J. G. and C. X. Z. conducted the experiment and analyzed the data. H. J. G. wrote the manuscript. C. X. Z. revised the manuscript. All authors reviewed and approved for publication.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Ethics approval had been obtained from the Ethics Committee of Shenyang Coloproctology Hospital and the informed consent was obtained from included patients.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gao, H., Zhang, C. miR-3133 is an unfavorable prognosis factor and tumor suppressor in colon cancer. Funct Integr Genomics 23, 132 (2023). https://doi.org/10.1007/s10142-023-01059-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01059-3